SEC Filing Summary: Oculus Innovative Sciences, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on November 19, 2008. The report addresses a regulatory compliance issue regarding the company's listing status on the Nasdaq Global Market.
Key Financial Metrics
The filing discloses that as of September 30, 2008, the company's stockholders' equity was less than the $10 million required for continued listing under Nasdaq Marketplace Rule 4450(a)(3). The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity beyond this equity deficiency.
Material Changes
The primary material event is the receipt of a Nasdaq Staff Deficiency Letter on November 19, 2008, notifying the registrant of non-compliance with continued listing standards due to insufficient stockholders' equity.
Outlook, Risks, and Management Commentary
Management intends to submit a plan to Nasdaq by December 4, 2008, to achieve and sustain compliance with listing requirements. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from expectations due to risks described in the company's Form 10-K. No specific financial guidance or unusual items were detailed in this report.
Investor Verification Checklist
- Verify the company's current stockholders' equity status relative to the $10 million Nasdaq threshold.
- Confirm whether a compliance plan was submitted to Nasdaq by the December 4, 2008 deadline.
- Review the company's most recent Form 10-K for detailed financial risks and historical performance.
- Monitor subsequent filings for updates on the listing status or potential delisting.